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Angiopoietin-1 is a promoter of physiological vasculogenesis and angiogenesis because it induces vascular branching and
smooth muscle recruitment to newly formed blood vessels. However, angiopoietin-1 expression in tumours appears to be
uncommon, and angiopoietin-1 overexpression in cancer cells has been reported to lead to inhibition of xenograft tumour
growth. We report here that angiopoietin-1 overexpression resulted in stabilization of tumour edge-associated blood vessels,
as it prevented vessel dilation and dissociation of smooth muscle cells from existing vessels. In addition, angiopoietin-1
stimulated an inﬁltration of mesenchymal cells into the tumours, such that the coverage of microvessels by pericytes increased
markedly, and the cancer cells were separated into small masses by the host stroma. The rates of both cancer cell proliferation
and apoptosis decreased signiﬁcantly in the presence of angiopoietin-1. Tie2, the receptor for angiopoietin-1, was found to be
present in vascular smooth muscle cells in culture in addition to endothelial cells. These ﬁndings suggest that a vascular
stabilization effect of angiopoietin-1 accounts for the inhibition of tumour growth.
British Journal of Cancer (2002) 86, 645–651. DOI: 10.1038/sj/bjc/6600082 www.bjcancer.com
ã 2002 Cancer Research UK
Keywords: angiopoietin; endothelial cells; smooth muscle; pericyte; tumour; vasculature
Interactions between endothelial cells and supporting mesenchymal
cells (smooth muscle cells and pericytes) are essential to blood
vessel development and function. Endothelial cells are in contact
with these supporting cells via functional gap junctions, separated
only by a fenestrated basement membrane (Bruns and Palade,
1968; Spitznas and Reale, 1975; Spagnoli et al, 1981; Leiser et al,
1985). The association of these cells is critical for vascular stabiliza-
tion, and is accompanied by the inhibition of endothelial cell
proliferation (Folkman and D’Amore, 1996; Hanahan and Folk-
man, 1996). Disruption of this endothelial/mesenchymal cell
association is seen in disease states such as angiogenesis in cancer
(Carmeliet and Jain, 2000) and restenosis after coronary angio-
plasty (Orford et al, 2000).
Angiopoietin-1 (Ang1) and the antagonistic ligand angiopoietin-
2 (Ang2) are important vascular regulatory molecules whose func-
tions have been the subjects of intensive investigation. Ang1 gene
expression in utero is closely associated with vascular endothelial
cell growth factor (VEGF, initially known as vascular permeability
factor, VPF (Dvorak et al, 1991)) and in physiological angiogenic
processes in adults such as ovulation (Maisonpierre et al, 1997).
Null mutation of the Ang1 gene in transgenic animals led to failure
of endothelial cells to form stable associations with supporting
mesenchymal cells and failure of primitive capillaries to develop
into a mature branched network (Suri et al, 1996). Transgenic
Ang1 over-expression resulted in increased vascular branching
(Suri et al, 1998). While overexpression of VEGF also led to
increased vascular branching, the vessels induced by VEGF were
leaky. By contrast, the vessels induced by Ang1 were not leaky
and resisted leakage caused by inﬂammatory agents, due to mark-
edly enhanced association of smooth muscle cells with the
endothelium. Co-expression of Ang1 and VEGF had an additive
effect on angiogenesis but gave rise to leakage-resistant vessels typi-
cal of Ang1 as seen when Ang1 was overexpressed alone (Thurston
et al, 1999, 2000).
In vitro, Ang1 protects against endothelial cell apoptosis, and
induces vascular sprouting and capillary-like tubule formation in
collagen (Koblizek et al, 1998; Hayes et al, 1999; Holash et al,
1999; Papapetropoulos et al, 1999). Ang1 has been shown to inter-
act with a receptor tyrosine kinase, Tie2, which is largely limited to
endothelial cells (Dumont et al, 1993; Maisonpierre et al, 1993;
Davis et al, 1996; Suri et al, 1996). Null mutation of the Tie2 gene
gave rise to essentially the same phenotype seen when Ang1 was
knocked out (Sato et al, 1995). It has also been reported that
Ang1 as well as Ang2 were direct substrates in endothelial cell
adhesion mediated by integrins (Carlson et al, 2001). Many studies
have investigated the expression patterns of Ang1, other angiopoie-
tins, and Tie2 in a variety of tumours, including cancers of the
breast (Hayes et al, 2000; Currie et al, 2001), brain (Stratmann et
al, 1998; Zagzag et al, 1999; Eggert et al, 2000), liver (Tanaka et
al, 1999), ovary (Martoglio et al, 2000), lung (Takahama et al,
1999; Wong et al, 2000), Kaposi’s sarcoma and cutaneous angiosar-
coma (Brown et al, 2000), thyroid gland (Bunone et al, 1999), and
leukaemia (Kukk et al, 1997). These studies revealed a complex
pattern of expression of the angiopoietins and Tie2 that is consis-
tent with an important role for Ang2 and VEGF in the
destabilization of vasculature and initiation of tumour angiogen-
esis. In contrast the role of Ang1 in cancer was less clear.
We recently reported (Hayes et al, 2000) that overexpression of
Ang1 in an MCF-7 xenograft model of tumour angiogenesis
resulted in a retardation of tumour growth and the extent of inhi-
bition correlated to the extent of Ang1 overexpression. Others also
reported a similar inhibition of colon cancer xenograft tumour
growth (Ahmad et al, 2001). We have now analyzed the MCF-7
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the structure of the tumour vasculature and the proliferation of
the cancer cells. We report here that Ang1 overexpression
prevented the dissociation of smooth muscle cell from the endothe-
lium of the tumour edge-associated blood vessels and the dilation
of these vessels. It also induced an inﬂux of stromal cells into the
tumours, which greatly enhanced the coverage of microvessels by
pericytes. The rates of cancer cell proliferation and apoptosis both
declined signiﬁcantly. These ﬁndings are consistent with the view
that stabilization and maturation of tumour neovasculature
induced by Ang1 has an inhibitory effect on tumour growth.
MATERIALS AND METHODS
Tumour model
Female athymic nude mice were ovariectomized and oestrogen-
pellet supplemented (Taconic Farms, Germantown, NY, USA).
Human breast cancer cell line MCF-7 was stably transfected with
full length Ang1 gene, and the secretion of Ang1 into the condi-
tioned media was determined as described (Hayes et al, 2000). In
vitro culture, harvest and inoculation of 5610
6 cells in the region
of the mammary fat pads of the mice was performed as described
(Hayes et al, 2000). Tumour volumes were measured in a blinded
manner. Tumours were dissected post mortem, bisected and half
was immediately frozen in liquid nitrogen and stored at 7808C.
The remaining tumour samples were ﬁxed with 2% formalde-
hyde/0.2% glutaraldehyde for 4 h, washed in PBS, and embedded
in parafﬁn. Ang1 expression in the xenograft tumours was deter-
mined by immunostaining parafﬁn sections (0.5 mm) with an
antibody to the N-terminus of Ang1 (L41309M, kindly provided
by Regeneron Inc., Tarrytown, NY, USA). A high standard of
animal ethics was applied in carrying out this investigation. We
assure that the animal ethics meet the standards required by the
current UKCCCR Guidelines (Workman et al, 1998).
Determination of microvessel density, peripheral vessel
density, and vessel lumen size
Three tumour specimens of medium size from each experimental
group were analyzed. Three random sections from each specimen
were prepared. The sections were immunostained for endothelial
cells with a rat monoclonal antibody to CD31 (M13.2, PharMin-
gen, San Diego, CA, USA). Microvascular density was determined
by manually counting CD31-positive vessels in 5*15 most vascu-
larized areas of each section under 4006 magniﬁcation as
described (Weidner and Folkman, 1996). Peripheral vascular
density was measured by counting CD31-positive vessels in the
stroma at the edge of the tumour. All edge-associated vessels were
counted in each section under 4006 magniﬁcation. The sizes of
the lumen of the tumour peripheral vessels were determined by
measuring the length and width of the cross sections of CD31-posi-
tive vessels, using the equation for elliptical areas S=p*(1/2
length)*(1/2 width).
Determination of cancer cell proliferation and apoptosis
rates
Cells undergoing proliferation at the time of sample collection were
identiﬁed by immunostaining the tumour sections for proliferating
cell nuclear antigen (PCNA) using a monoclonal antibody (PC-10,
Santa Cruz Biochemicals, Santa Cruz, CA, USA) (Hall et al, 1990).
The number of PCNA-positive cancer cells and the total number of
cancer cells in at least nine randomly selected areas of each section
were manually counted under 4006 magniﬁcation. Three tumours
per experimental group and three random sections per tumour
were analyzed. Cell apoptosis rate was determined from tumour
sections subjected to in situ TUNEL assay (Gavrieli et al, 1992)
by using a cell death detection kit (Roche Biochemicals,
Mannheim, Germany). The number of apoptotic cells was deter-
mined in a manner similar to the determination of microvessel
density. Thus, the highest number of BrdU-positive cells in at least
nine most apoptotic areas in each section were manually counted.
Three tumours per experimental group and three random sections
per tumour were analyzed.
Determination of vascular smooth muscle-endothelial cell
ratio
Tumour sections were immunostained for smooth muscle cells,
using a monoclonal antibody to mouse a-smooth muscle actin
(1A4, Sigma, St. Louis, MO, USA) and an FITC-conjugated anti-
mouse IgG (Sigma), and for endothelial cells, using a rat monoclo-
nal antibody to mouse CD31 and a TRITC-conjugated anti-rat IgG
(Sigma). A mouse-on-mouse blocking kit (Vector, Burlinghame,
CA, USA) was used to block non-speciﬁc interactions when anti-
mouse antibodies were used. The cells were visualized under an
Olympus confocal laser scanning microscope. Computer-assisted
image analysis of the photographs of the blood vessels was carried
out by using an image analysis software Optimas 5.2 (Media
Cybernetics, Baltimore, MD, USA), which allows the recognition
of different colours and the measurement of the areas occupied
by each colour.
Analysis of mesenchymal cell inﬁltration
Parafﬁn-embedded tumour sections were immunostained for
endothelial cells with biotinylated Griffonia (Bandeiraca) simplicifo-
lia lectin I isolectin B4 (Vector), and for smooth muscle cells with
the anti-a-smooth muscle actin.
Western analysis of Tie2 expression
Cell lysates were prepared from semi-conﬂuent cultures of human
umbilical cord vein endothelial cells (HUVEC; Clonetics, NC,
USA), human coronary artery smooth muscle cells (CASMC;
Clonetics), human dermal ﬁbroblast cells (Clonetics), adult bovine
aortic endothelial cells (ABAE; a gift from Peter Bohlen of ImClone,
NY, USA), Chinese hamster ovary (CHO) cells (ATCC, American
Type Culture Collection, Manassas, VA, USA), human breast cancer
cell line MDA-MB-231 cells (ATCC), and the Ang1 transfected
MCF-7 cells (clone 128), as well as vector transfected control cells,
as indicated. The cell lysates were subject to SDS–PAGE and
Western blotting analysis by using an anti-Tie2 antibody (sc-324,
Santa Cruz Biochemicals).
RESULTS
Inhibition of breast cancer MCF-7 xenograft tumour
growth by Ang1 overexpression
We reported previously that tumours formed by Ang1-transfected
MCF-7 cells in nude mice grew at a much slower rate than did
the parental or vector-transfected cells (Hayes et al, 2000). Three
Ang1-overexpressing clones are shown, together with the parental
MCF-7 and the vector-transfection controls. Ang1 is produced by
these cell lines as a secreted protein. The yields of Ang1 in the
conditioned media of clone-166, clone-128, and clone-184 are,
respectively, 160 ng ml
71, 240 ng ml
71, and 820 ng ml
71. The
higher level of Ang1 production by the cells, the slower the growth
rate of the tumours formed by the cells (Figure 1a). The tumours
were retrieved at the end of the experiment, and Ang1 expression
levels in the tumours assessed by immunostaining. A signiﬁcant
proportion of the Ang1-transfected cancer cells were producing
Ang1 in the tumours (Figure 1b). In comparison, little Ang1 was
detectable in the control MCF-7 tumour (Figure 1c).
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and prevents the dissociation of smooth muscle cells from
endothelial cells
Intratumoural microvessel density was similar between Ang1 over-
expressing tumours and controls (Table 1), despite the much
decreased tumour growth rate seen with Ang1 overexpression. In
addition, there was no discernible change in the density of the
tumour edge-associated blood vessels (Table 1). However the
morphology of the tumour edge-associated vessels was altered
strikingly by Ang1 over-expression. Tumours formed by the paren-
tal MCF-7 cells typically possessed extremely ectatic blood vessels
with large calibre lumens at the edge of the tumour. Such dilated
vessels were absent in tumours overexpressing Ang1. The edge-
associated vessels in the stroma of MCF-7 tumours were poorly
supported by smooth muscle cells. This was evident from double
immunostaining of the endothelial cells (CD31 and TRITC) and
smooth muscle cells (aSMA and green FITC) of these vessels. Many
edge-associated vessels in the parental MCF-7 tumours had a thin
and discontinuous layer of smooth muscle (Figure 2a). Some of the
edge-associated vessels retained a normal layer of smooth muscle.
In contrast, most of the edge-associated vessels in Ang1-overex-
pressing tumours were well supported by a continuous layer of
smooth muscle cells (Figure 2b). We quantitatively determined
smooth muscle-to-endothelial cell ratio in the walls of the tumour
edge-associated vessels by measuring the areas occupied by the red
colour, which represents endothelial cells, and the areas occupied
by the green colour, which represents smooth muscle cells. This
smooth muscle-to-endothelial cell ratio was nearly three times
higher in the peripheral blood vessels in the Ang1-overexpressing
tumours, as compared with that in the control tumours (Table
1). We then compared the lumen sizes of the peripheral vessels in
the two groups of tumours positively identiﬁed by CD31 staining.
We assumed a typical elliptic shape of the cross-section of the
vessel lumen. The average lumen size of the peripheral blood
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Figure 1 Inhibition of MCF-7 tumour growth by Ang1 overexpression. (a) The bars represent the average volumes (+s.e., n=10) of xenograft tumours
formed by MCF-7 cell lines, in the order that they appear in each group: parental MCF-7, vector-transfected, Ang1-overexpressing clone-166, clone-128, and
clone-184. *P50.05 (ANOVA) compared with the parental MCF-7 control. **P50.05 compared with the vector-transfection control. (b,c) Immunostain-
ing of retrieved xenograft tumours for Ang1 production by Ang1-transfected cancer cells (b) and the control MCF-7 cells (c).
Table 1 Characteristics of the vasculature in MCF-7 xenograft tumours
formed by Ang1 overexpressing cells and vector-transfected control cells.
Three tumour specimens of medium size from the vector-control group
and each of the Ang1 overexpressing groups were analyzed. Three ran-
dom sections from each specimen were prepared and analyzed as de-
scribed in Materials and Methods and in footnotes below
Ang1
Vector Control overexpression
(+s.e.) (+s.e.) ANOVA
MVD
a 19+1 n=50 16+1 n=50 P50.01
PVD
b 22+2 n=27 23+1 n=29 P40.1
SM/EC ratio
c 0.81+0.14 n=21 2.17+0.13 n=10 P50.01
Edge vessel size
d 4581.5+1992.4 n=71 2167.5+1056.8 n=49 P50.05
PCNA+
e 73.6+1.9 n=15 34.5+2.1 n=15 P50.0001
Apoptosis extent
f 14+2 n=16 6+1 n=15 P50.0001
aMVD is microvessel density, expressed as the number of microvessels per 6400
ﬁeld; n is the number of ﬁelds counted;
bPVD is peripheral vessel density deter-
mined as the number of tumour edge-associated vessels per 6400 ﬁled; n is the
number of ﬁelds counted;
cSM/EC ratio is a relative smooth muscle-to-endothelial
cell ratio per cross-section of one blood vessel; see Materials and Methods for
detail); n is the number of vessels counted;
dEdge vessel size is the size of a cross
section of a tumour peripheral blood vessel (mm
2; see Materials and Methods for
detail); n is the number of vessels measured;
ePCNA+ is the percentage (%) of
PCNA positive cancer cells out of all cancer cells in a tumour; n is the number of
ﬁelds counted;
fApoptosis extent is the number of apoptotic cells per 6400 ﬁeld;
n is the number of ﬁelds counted.
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 86(4), 645–651vessels in the control tumours is more than twice that of the Ang1-
overexpressing tumours (Table 1) suggesting a correlation between
dissociation of smooth muscle cells and dilation of the tumour
blood vessels. These results indicate that Ang1 stabilized the exist-
ing blood vessels at the tumour edge by preventing the dissociation
of smooth muscle cells from the endothelium.
Ang1 enhances microvessel coverage by pericytes
We examined the blood vessels inside the tumours and found that
there was a marked inﬁltration of SMA-positive cells into the
Ang1-overexpressing MCF-7 tumours. The tumours formed by
parental MCF-7 cells consisted of a large, continuous mass of
cancer cells with microvessels. The vessels were scarce, thin, and
occasionally covered by SMA-positive pericytes (Figure 3a). The
interior of the tumours formed by the Ang1-transfected MCF-7
cells, however, was remarkably different. The cancer cells in these
tumours formed small, isolated masses separated by the host stro-
ma made of an abundant number of SMA-positive cells that were
almost always associated with microvessels (Figure 3b). The results
indicate that the number of pericyte-associated microvessels
increased signiﬁcantly in the presence of Ang1. Ang1 thus facili-
tated the maturation of the tumour vasculature by inducing an
inﬂux of mesenchymal cells into the tumour and promoted the
formation of blood vessels well-supported by smooth muscle cells
and pericytes. Tie2, the receptor for Ang1, has been shown to be
predominantly an endothelial cell-speciﬁc gene. The marked inﬁl-
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Figure 2 Ang1 prevents dissociation of smooth muscle cells from
tumour edge-associated vessels. Confocal microscopic images of tumour
edge-associated vessels were obtained by double immuno-ﬂuorescent
staining. Original magniﬁcation x200. Endothelial cells (red) were
immunostained for CD31 and visualized with TRITC. Smooth muscle cells
(green) were immunostained for a-actin and visualized with Green-FITC.
(a) Many peripheral blood vessels in the control MCF-7 tumours are highly
dilated and poorly supported by smooth muscle (arrow). Some blood ves-
sels appear to have a normal smooth muscle layer (arrow head). (b) A ty-
pical edge-associated vessel in Ang1-overexpressing tumours showing an
undilated lumen with good smooth muscle support.
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Figure 3 Ang1 overexpression causes marked inﬁltration of smooth
muscle cells into tumours. (a) Microscopic image of a section of control
MCF-7 tumours. (b) Microscopic image of a section of Ang1-overexpres-
sing tumours. Tumour sections were immunostained for smooth muscle
cells with antibody to a-smooth muscle actin and DAB substrate (brown)
and endothelial cells with biotinylated Griffonia (Bandeiraca) simplicifolia lec-
tin I isolectin B4 and Vector Red (red), and counter stained with Gill’s hae-
matoxylin (blue). Original magniﬁcation 6100. (c) Tie2 expression in
vascular smooth muscle cells and endothelial cells in culture. Total cell ly-
sates prepared from conﬂuent cell cultures were analyzed by Western
blotting. MW, molecular weight standard; MPCX-Ang1, Ang1-transfected
MCF-7 cells; MPCXPool, vector-transfected MCF-7 cells. Fibroblast, human
dermal ﬁbroblast cells; HUVEC, human umbilical cord vein endothelial cells;
ABAE, adult bovine aortic endothelial cells; MDA-MB-231, human breast
cancer cell line; CHO, Chinese hamster ovary cells; CASMC; human coron-
ary artery smooth muscle cells.
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7 tumours, however, prompted us to determine whether vascular
smooth muscle cells also expressed Tie2. Western blotting analysis
of a number of different types of cells indicated that cultured
human vascular smooth muscle cells express Tie2 under the experi-
mental conditions, although the level of expression is much lower
than that in endothelial cells (Figure 3c). This suggests that Ang1
may be able to act directly on smooth muscle cells to facilitate their
inﬁltration into the tumours.
Decreased cancer cell proliferation and apoptosis in
Ang1-overexpressing tumour
We investigated the growth rate of the Ang1-transfected cancer
cells in the tumours as well as in cell cultures. The tumour
sections were stained for proliferating cell nuclear antigen
(PCNA). The PCNA-positive cells were counted. Most of the
cancer cells in the control MCF-7 tumours were undergoing
proliferation (Figure 4a, Table 1). In contrast, a much smaller
fraction of the cancer cells were growing in Ang1-overexpressing
tumours (Figure 4b, Table 1). The inhibitory effect on the growth
of the xenograft tumours was not a direct activity of Ang1 on
cancer cells, since Ang1-transfection had no effect on the growth
rate of the cancer cells in culture as assessed by an in vitro mito-
genesis assay utilizing a colorimetric vital dye (data not shown).
We then determined the impact of Ang1 on the apoptosis rate
of the cancer cells by measuring BrdU incorporation into frag-
mented nuclear DNA molecules occurring during programmed
cell death. Many cancer cells in the control MCF-7 tumours
underwent apoptosis, usually in groups (Figure 4c). There were,
however, no such pockets of apoptotic cells in the Ang1-overex-
pressing tumours (Figure 4d). We determined the average
number of apoptotic cells in a given tumour section, and found
that it decreased in the presence of Ang1 to about one-third that
of the control group (Table 1). These results, together with the
decreased PCNA staining of the cancer cells, indicate that the
cancer cells in Ang1-overexpressing tumours had become relatively
quiescent.
DISCUSSION
Destabilization of existing blood vessels is an essential step in the
initiation of tumour angiogenesis (Gimbrone et al, 1972). This
study indicates that Ang1 may mediate vascular stabilization by
acting on the mesenchymal component of the tumour. The action
appears to result in a strengthening of the existing blood vessels
surrounding a tumour, and an enhancement of smooth muscle cell
and pericyte population in the tumour. These effects apparently
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Figure 4 Ang1-overexpression coincides with a decrease of cancer cell proliferation and apoptosis. Tumour sections were immunostained for PCNA
with DAB-Ni substrate (black), counter stained with Gill’s haematoxylin (blue). Original magniﬁcation 6400. (a) Microscopic image of a section of
MCF-7 tumours. (b) Microscopic image of a section of Ang1-overexpressing tumours. Apoptotic cells are identiﬁed by in-situ TUNEL labelling visualized
with TMR-Red (red). Original magniﬁcation 6200. (c) Confocal microscopic image of a typical apoptotic cell population in the control parental MCF-7
tumours. (d) Confocal microscopic image of the Ang1-overexpressing tumours.
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have observed (Hayes et al, 2000; Ahmad et al, 2001).
The process of tumour angiogenesis has been likened to a
wound that fails to heal with a continuous cycle of vascular sprout-
ing, exudation of tissue ﬂuid, and invasion of mesenchymal cells
(Dvorak, 1986). As a result, the tumour vessels have irregular
diameters, frequent intussusception and irregular branching
patterns. They have incomplete basement membranes and discon-
tinuous pericyte coatings (Carmeliet and Jain, 2000). The
aberrant structure and function of the tumour vascular system
not only allows but stimulates the ongoing angiogenic processes
of capillary sprouting and exudation of stroma as the tumour
continues to grow.
The histopathological analysis of the MCF-7 xenograft tumours
revealed a number of important activities of Ang1. First, Ang1-
overexpression is correlated to stabilization of the vessels at the
leading edge of tumour growth. This is evident from the preven-
tion of vessel dilation and the maintenance of regular pericyte
support of the vessel wall. Second, Ang1-overexpression coincides
with the inﬁltration of an excess of mesenchymal cells into the
tumour, comprising principally, though not exclusively, smooth
muscle cells. These cells become associated with endothelial cells
to form a vascular system surrounding nests of tumour cells. Third,
the rates of both cancer cell proliferation and apoptosis are
substantially diminished in the Ang1 overexpressing tumours. This
cannot be ascribed to a direct inhibitory activity of Ang1 on the
cancer cells, as MCF-7 cell growth rate in culture is not altered
by overexpression of Ang1.
The important question is why the effects of Ang1 overexpres-
sion in tumours result in a retardation of growth. It is plausible
that the stabilization effect of Ang1 on the ectatic vessels at the
periphery of the tumour is of particular signiﬁcance. Recent studies
have shown that an angiogenic response induced by overexpression
of VEGF/VPF involved the formation of highly permeable,
enlarged, thin-walled, and pericyte-poor variations of blood vessels.
These vessels developed from pre-existing microvessels after
pericyte detachment and basement membrane degradation
(Pettersson et al, 2000). They are similar to those seen here in
the periphery of the parental MCF-7 tumours, which are known
to express VEGF (Heer et al, 1998; Ruohola et al, 1999). It is
known that Ang1 can act to prevent the permeability effects of
VEGF by its effect on endothelial cell-pericyte association (Thur-
ston et al, 1999, 2000). It is therefore reasonable to surmise that
the crucial event in the ongoing growth of a tumour is the desta-
bilization of native vessels at the tumour periphery as a result of
VEGF expression, producing ectatic and highly permeable vessels.
Ang1 appears to be able to prevent this process presumably by
stabilizing the pericyte-endothelial cell association. This in turn
results in a negative effect on the growth of the tumour cells which
accounts for the changes in rates of tumour cell proliferation and
apoptosis. It has long been recognized that the growth rate of a
tumour is not proportional to the growth rate of the cancer cells
but to that of the blood vessels (Tannock, 1968). It is plausible that
tumour growth diminishes when the tumour is unable to initiate
angiogenesis from a vasculature stabilized by Ang1.
The molecular mechanism by which Ang1 exerts its effects on
the endothelial-mesenchymal association is not clear. The current
hypothesis is that, since Tie2, the receptor for Ang1, is primarily
limited to endothelial cells, the recruitment of mesenchymal cells
to a newly formed blood vessel is the result of a paracrine loop
between endothelial cells, which respond to Ang1, and the
mesenchymal cells which respond to intermediary signalling mole-
cules released by the endothelial cells (Folkman and D’Amore,
1996). Putative intermediary molecules have been suggested but
such a paracrine loop has yet to be identiﬁed. Our ﬁndings that
smooth muscle cells express Tie2 in culture, and that a large
number of smooth muscle cells inﬁltrate into Ang1-overexpressing
tumours suggest a direct role of Ang1 on mesenchymal cells under
certain conditions to facilitate vascular stabilization. It is important
to point out that our observations are limited to an experimental
breast cancer model, although they have been reﬂected in a study
on a colon cancer model by others (Ahmad et al, 2001). Whether
Ang1 plays a similar role under clinical conditions remains unclear.
Further studies should be directed to explore this interesting role.
The therapeutic potential of Ang1 either as recombinant proteins
or delivered by means of gene transfer should also be investigated.
Current anti-angiogenic approaches focus on targeting endo-
thelial cells. Our study suggests that mesenchymal vascular compo-
nents should also be emphasized. Tumour angiogenesis is not
simply reliant upon the division of endothelial cells but also
involves processes such as vascular destabilization and vascular
permeability changes. The identiﬁcation of Ang1 as a molecule that
may alter these processes and so retard tumour growth opens new
avenues for intervention on the tumour angiogenic process.
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